



AUTHOR CORRECTION

Author Correction: Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth

Qi Qi¹, Xia Liu¹, Shiyong Li¹, Harish C. Joshi² and Keqiang Ye¹

Acta Pharmacologica Sinica (2022) 43:1100; <https://doi.org/10.1038/s41401-021-00762-w>

Correction to: *Acta Pharmacologica Sinica* <https://doi.org/10.1038/aps.2013.40>, published online 27 May 2013

The authors apologize that in Fig. 3D, there are duplicate pictures of the active caspase-3 staining between TMZ-treated group and CIS-treated group. The corrected version of Fig. 3D has been provided below. The authors declare that these corrections do not change the results or conclusions of this paper.

The authors apologize that in Fig. 2C, although the tumor volume data were shown in Fig. 2A, the size of the tumors in vehicle-treated appeared so big, which raised the concern that this experiment contravened the guidelines of the welfare and use of animals. To address the concern, the authors looked into the whole procedures of the experiment and confirmed that no violation happened in the experiment based on the protocol that approved by Emory IACUC in year 2011.




Fig. 3 D Combination treatment enhanced active-caspase-3 expression and decreased Ki67 expression in vivo. Immunohistochemical staining of active-caspase-3 and Ki67 in tumor sections derived from animals treated with indicated drugs. Brown represents the positively staining cells (arrows). Bar represents 100 μ m. NOS, noscapine; TMZ, temozolamide; BCNU, bis-chloroethylnitrosourea; CIS, cisplatin.

¹Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA and ²Department of Cell Biology, Emory University School of Medicine, Atlanta, GA 30322, USA

Correspondence: Keqiang Ye (kye@emory.edu)